Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

Summary

The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. Subjects will receive 2 vaccinations with the Biojector® 2000, and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. The safety and immune system's response will be studied throughout the trial.

Timeline

Start

2007-08

Primary completion

2008-09

Completion

2011-02

Drugs

Indications